Table 2 Antibiotic use in the population-based cohorts by period before fecal sampling
SCAPIS | SIMPLER | MOS | |||||||
|---|---|---|---|---|---|---|---|---|---|
Period | <1 year | 1–4 years | 4–8 years | <1 year | 1–4 years | 4–8 years | <1 year | 1–4 years | 4–8 years |
Penicillin V | 559 (6.6%) | 1,501 (17.7%) | 2,124 (25%) | 272 (5.7%) | 915 (19.1%) | 1,266 (26.5%) | 109 (6.4%) | 332 (19.4%) | 482 (28.2%) |
Tetracyclines | 287 (3.4%) | 858 (10.1%) | 1,405 (16.6%) | 146 (3.1%) | 420 (8.8%) | 704 (14.7%) | 60 (3.5%) | 189 (11.1%) | 265 (15.5%) |
Penicillins ES | 301 (3.5%) | 824 (9.7%) | 1,013 (11.9%) | 201 (4.2%) | 559 (11.7%) | 615 (12.9%) | 48 (2.8%) | 149 (8.7%) | 209 (12.2%) |
Flucloxacillin | 166 (2%) | 570 (6.7%) | 732 (8.6%) | 120 (2.5%) | 349 (7.3%) | 428 (8.9%) | 28 (1.6%) | 104 (6.1%) | 142 (8.3%) |
Fluoroquinolones | 136 (1.6%) | 384 (4.5%) | 506 (6%) | 126 (2.6%) | 361 (7.5%) | 480 (10%) | 12 (0.7%) | 56 (3.3%) | 69 (4%) |
Nitrofurantoin | 138 (1.6%) | 374 (4.4%) | 331 (3.9%) | 113 (2.4%) | 288 (6%) | 272 (5.7%) | 23 (1.3%) | 87 (5.1%) | 61 (3.6%) |
Clindamycin | 104 (1.2%) | 298 (3.5%) | 387 (4.6%) | 37 (0.8%) | 131 (2.7%) | 160 (3.3%) | 20 (1.2%) | 64 (3.7%) | 83 (4.9%) |
Sulfamethoxazole-trimethoprim | 38 (0.4%) | 142 (1.7%) | 209 (2.5%) | 46 (1%) | 132 (2.8%) | 196 (4.1%) | 2 (0.1%) | 27 (1.6%) | 52 (3%) |
Cephalosporins | 46 (0.5%) | 142 (1.7%) | 247 (2.9%) | 19 (0.4%) | 52 (1.1%) | 119 (2.5%) | 16 (0.9%) | 45 (2.6%) | 77 (4.5%) |
Macrolides | 42 (0.5%) | 132 (1.6%) | 243 (2.9%) | 12 (0.3%) | 51 (1.1%) | 81 (1.7%) | 15 (0.9%) | 42 (2.5%) | 65 (3.8%) |
Amoxicillin-clavulanic acid | 33 (0.4%) | 76 (0.9%) | 111 (1.3%) | 9 (0.2%) | 39 (0.8%) | 60 (1.3%) | 2 (0.1%) | 9 (0.5%) | 17 (1%) |
